New Hope for Patients with Cancer

Cancer is relentless. A diagnosis can be devastating because cancer never rests. That is why we are excited to announce the proposed acquisition of Seagen. We plan to combine our expertise with Seagen’s and deliver a powerful cancer-fighting technology called antibody-drug conjugates (ADCs) to the world. Watch to learn more about the potential of ADCs and how this proposed acquisition could help us transform the future of cancer care.